Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 18/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 16/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 11/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 3/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.77 |
| ▸ | MTOR | P42345 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2950985 | 0.91 | PIK3CB (0.83) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL2953079 | 0.90 | PIK3CD (0.81) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL16308630 | 0.89 | PIK3CD (0.80) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL15029422 | 0.89 | PIK3CB (0.80) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL2948221 | 0.89 | PIK3CD (0.80) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL2953032 | 0.89 | PIK3CD (0.80) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL2947730 | 0.89 | PIK3CD (0.82) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL2593015 | 0.89 | PIK3CD (0.80) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL15582985 | 0.88 | PIK3CD (1.00) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL15583160 | 0.88 | PIK3CD (1.00) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338414-B2 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-12-25 | — | — | US | claimed |
| EP-1864665-B1 | IMMUNOSUPPRESSIVE AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2012-05-16 | — | — | EP | claimed |
| US-20100267700-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2010-10-21 | — | — | US | claimed |
| US-20080113987-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-05-15 | — | — | US | claimed |
| EP-1864665-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-12-12 | — | — | EP | claimed |
| EP-3481822-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-06-22 | — | — | EP | disclosed |
| US-10919877-B2 | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190224207-A1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-25 | — | — | US | disclosed |
| US-9611258-B2 | Dual MEK/PI3K inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160002212-A1 | DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-01-07 | — | — | US | disclosed |
| EP-2411387-B1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | VETDC INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-9108980-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| EP-1864665-B1 | IMMUNOSUPPRESSIVE AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2012-05-16 | — | — | EP | disclosed |
| EP-2411387-A2 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | Pathway Therapeutics, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20100267700-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2010-10-21 | — | — | US | disclosed |
| WO-2010110685-A2 | PYRIMDDINYL AND 1,3,5-TRIAZINYL BENZIMTOAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | US | disclosed |
| US-7750001-B2 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20080113987-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1864665-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267700-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | IL2, NFATC1, CD47 | PIK3CD 1584/4885PIK3CB 2354/4885PIK3CA 2655/4885 |
| US-20160002212-A1 | DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | MAP2K2, MAP2K1, MAP2K7 | PIK3CD 26/4885PIK3CB 33/4885PIK3CA 10/4885 |
| US-20080113987-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | IL2, NFATC1, CD47 | PIK3CD 1584/4885PIK3CB 2354/4885PIK3CA 2655/4885 |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | PIK3CD 499/4885PIK3CB 172/4885PIK3CA 99/4885 |
| US-10919877-B2 | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | MTOR, PIK3CA, MAPKAP1 | PIK3CD 10/4885PIK3CB 16/4885PIK3CA 2/4885 |
| US-20190224207-A1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | MTOR, PIK3CA, MAPKAP1 | PIK3CD 10/4885PIK3CB 16/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.